Stock Track | Tempus AI Soars 5.31% as Subsidiary Ambry Genetics Reports Breakthrough in Rare Disease Diagnosis

Stock Track

May 27, 2025

Tempus AI (TEM) stock is soaring 5.31% in pre-market trading on Tuesday, following a significant announcement from its subsidiary, Ambry Genetics. The company has published a study in Genetics in Medicine, showcasing the success of its Patient for Life™ program in enhancing rare disease diagnosis.

The groundbreaking program involves proactive reanalysis of exome test data, utilizing newly discovered gene-disease associations and emerging evidence to reclassify genetic variants. This innovative approach has led to diagnoses in 5% of cases that were initially negative or uninformative, offering renewed hope for patients with rare diseases.

Investors appear to be reacting positively to this development, recognizing its potential to transform diagnostic outcomes in the rare disease field. The success of Ambry Genetics' program not only highlights Tempus AI's strategic investments in cutting-edge healthcare technologies but also positions the company at the forefront of personalized medicine and genetic testing advancements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136611599"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136611599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136611599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-27 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136611599","market":"us","top_or_hot":-1,"title":"Stock Track | Tempus AI Soars 5.31% as Subsidiary Ambry Genetics Reports Breakthrough in Rare Disease Diagnosis","media":"Stock Track","content":"<p>Tempus AI (TEM) stock is soaring 5.31% in pre-market trading on Tuesday, following a significant announcement from its subsidiary, Ambry Genetics. The company has published a study in Genetics in Medicine, showcasing the success of its Patient for Life™ program in enhancing rare disease diagnosis.</p>\n\n<p>The groundbreaking program involves proactive reanalysis of exome test data, utilizing newly discovered gene-disease associations and emerging evidence to reclassify genetic variants. This innovative approach has led to diagnoses in 5% of cases that were initially negative or uninformative, offering renewed hope for patients with rare diseases.</p>\n\n<p>Investors appear to be reacting positively to this development, recognizing its potential to transform diagnostic outcomes in the rare disease field. The success of Ambry Genetics' program not only highlights Tempus AI's strategic investments in cutting-edge healthcare technologies but also positions the company at the forefront of personalized medicine and genetic testing advancements.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tempus AI Soars 5.31% as Subsidiary Ambry Genetics Reports Breakthrough in Rare Disease Diagnosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tempus AI Soars 5.31% as Subsidiary Ambry Genetics Reports Breakthrough in Rare Disease Diagnosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-27 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tempus AI (TEM) stock is soaring 5.31% in pre-market trading on Tuesday, following a significant announcement from its subsidiary, Ambry Genetics. The company has published a study in Genetics in Medicine, showcasing the success of its Patient for Life™ program in enhancing rare disease diagnosis.</p>\n\n<p>The groundbreaking program involves proactive reanalysis of exome test data, utilizing newly discovered gene-disease associations and emerging evidence to reclassify genetic variants. This innovative approach has led to diagnoses in 5% of cases that were initially negative or uninformative, offering renewed hope for patients with rare diseases.</p>\n\n<p>Investors appear to be reacting positively to this development, recognizing its potential to transform diagnostic outcomes in the rare disease field. The success of Ambry Genetics' program not only highlights Tempus AI's strategic investments in cutting-edge healthcare technologies but also positions the company at the forefront of personalized medicine and genetic testing advancements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1136611599","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136611599","pubTimestamp":1748352812,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tempus AI  stock is soaring 5.31% in pre-market trading on Tuesday, following a significant announcement from its subsidiary, Ambry Genetics. The company has published a study in Genetics in Medicine, showcasing the success of its Patient for Life program in enhancing rare disease diagnosis.The groundbreaking program involves proactive reanalysis of exome test data, utilizing newly discovered gene-disease associations and emerging evidence to reclassify genetic variants. This innovative approach","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"子公司Ambry Genetics报告罕见病诊断取得突破，股票赛道Tempus AI飙升5.31%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"Tempus AI (TEM) stock is soaring 5.31% in pre-market trading on Tuesday, following a significant announcement from its subsidiary, Ambry Genetics. The company has published a study in Genetics in Medicine, showcasing the success of its Patient for Life™ program in enhancing rare disease diagnosis.\nThe groundbreaking program involves proactive reanalysis of exome test data, utilizing newly discovered gene-disease associations and emerging evidence to reclassify genetic variants. This innovative approach has led to diagnoses in 5% of cases that were initially negative or uninformative, offering renewed hope for patients with rare diseases.\nInvestors appear to be reacting positively to this development, recognizing its potential to transform diagnostic outcomes in the rare disease field. The success of Ambry Genetics' program not only highlights Tempus AI's strategic investments in cutting-edge healthcare technologies but also positions the company at the forefront of personalized medicine and genetic testing advancements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}